Kairos pharma, ltd.KAPA.US Overview

US StockHealthcare

(No presentation for KAPA)

Overview AI Analysis AI Earnings Summary Financials Financial Forecast Stock Sentimental Institutions TradingView Chart

KAPA Overall Performance

KAPA AI Analysis & Strategy

KAPA Recent Performance

2.06%

Kairos pharma, ltd.

0.81%

Avg of Sector

-1.14%

S&P500

KAPA PowerScanner

KAPA Key Information

KAPA Valuation Metrics

KAPA Earnings Table

KAPA Profile

Kairos Pharma, Ltd. operates as a clinical-stage biopharmaceutical company that develops therapeutics for cancer patients. Its therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. Kairos Pharma, Ltd. was formerly known as NanoGB13, Inc. and changed its name to Kairos Pharma, Ltd. in July 2016. The company was incorporated in 2013 and is based in Los Angeles, California.